Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Angiogenesis, Ophthalmic, and Preeclampsia Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for VEGFR-1/FLT-1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VEGFR-1/FLT-1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed. |
View FLT1 Products |
| Gene Delivery | FLT1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserve native conformation for cell-based assays. |
View FLT1 Products |
| Benchmark Ab | Anti-VEGFR-1 (Sequence of Icrucumab) Recombinant positive control. Sequence verified. |
View FLT1 Products |
| Validator | FLT1 siRNA Set For knockdown verification and specificity controls. |
View FLT1 Products |
| Related Target A | KDR (VEGFR-2) Selectivity counter-screening for biologic and TKI programs. |
View KDR Products |
| Related Target B | PIGF (Placental Growth Factor) FLT1-specific ligand; key pathway partner for angiogenesis and inflammation. |
View PIGF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human / Mouse / Cyno ortholog proteins available with >95% purity. Sequence verified. |
| Subfamily counter screening (VEGFR-1 vs VEGFR-2) | Homolog panel proteins (FLT1 vs KDR ECD) strictly verified by mass spec. Endotoxin controlled. |
| Ligand binding interference & Glycosylation dependency | HEK293 expressed antigens preserving native glycosylation patterns for accurate SPR/BLI kinetics. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included. |
| False Positives in Cellular Assays | Validated siRNA included for specificity checks and pathway isolation. |
| Internalization & Ligand Binding (ADC / Trap) | High-purity ECD-Fc with native glycosylation preserves PIGF/VEGFA binding epitopes. |
Live VEGFR-1/FLT-1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VEGFR-1 (FLT-1) therapeutics is intensifying, with major players continuing to refine multi-kinase inhibitors, monoclonal antibodies, and engineered receptor traps. The clinically validated Aflibercept fusion protein (Regeneron/Sanofi) incorporates FLT1 domains for Placental Growth Factor (PIGF) neutralization, establishing proof-of-concept for FLT1-directed trap modalities. Meanwhile, earlier selective antibody programs such as Icrucumab (Eli Lilly/ImClone) highlighted the need for differentiated epitopes and combination strategies. As multi-targeted TKIs with FLT1 activity remain approved but non-selective, the next wave of R&D is targeting selective FLT1 inhibition, ADCs directed to the tumor microenvironment, and sFLT1 clearance modalities for preeclampsia. First-generation anti-angiogenic therapies maturing in the clinic are now giving way to localized delivery (e.g., intravitreal injections for retinal diseases) and bispecific constructs that block multiple pro-angiogenic pathways to overcome resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Receptor Trap / Fusion Protein | Regeneron, Sanofi, Bayer | Wet AMD, mCRC, Gynecologic Cancers, Macular Degeneration | Ligand Competition Assay (Need high-purity FLT1 ECD-Fc with correct domain folding) |
| Multi-target TKI | Pfizer, Bayer, Eisai, Novartis | Solid Tumors (RCC, HCC, GIST) | Kinase Selectivity Assay (Need FLT1 WT vs KDR mutant kinase domain proteins) |
| Monoclonal Antibody | Eli Lilly / ImClone (Historical) | Solid Tumors | Epitope Binning & Selectivity (Need FLT1 vs KDR cross-reactive panel) |
| ADC / Bispecific (Emerging) | Undisclosed Biotech Programs | Oncology (Tumor Stroma), Refractory Solid Tumors | Internalization Assay (Need full-length Lentivirus stable cell line) |